Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01960478|
Recruitment Status : Unknown
Verified October 2013 by University Hospital, Strasbourg, France.
Recruitment status was: Not yet recruiting
First Posted : October 10, 2013
Last Update Posted : October 11, 2013
In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " The CVA National Action Plan 2013-2014".
Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin plasma level, as for Vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. This link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, CVA.
Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Vascular Accident (CVA)||Biological: (for each intervention) Other: Blood test||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||March 2016|
Biological: (for each intervention)
Other: Blood test
- Determine the minimum level of Copeptin required to determine if the patients present with acute CVA or not. [ Time Frame: Participants will be followed during 90 days ]Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimers in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01960478
|Contact: Sébastien HARSCOAT||3 69 55 13 70 ext email@example.com|
|Service des Urgences Médico-Chirugicales Adultes Hôpitaux Universitaires||Not yet recruiting|
|Strasbourg, France, 67098|
|Contact: Sébastien HARSCOAT 03 69 55 13 70 ext 0033 firstname.lastname@example.org|
|Sub-Investigator: Valérie WOLFF|
|Sub-Investigator: Christian MARESCAUX|
|Sub-Investigator: Valérie LAUER|
|Sub-Investigator: Pascal BILBAULT|
|Principal Investigator:||Sébastien HARSCOAT||Hôpitaux Universitaires de Strasbourg|